{"id":532,"date":"2018-07-09T11:03:08","date_gmt":"2018-07-09T11:03:08","guid":{"rendered":""},"modified":"2018-07-10T15:52:01","modified_gmt":"2018-07-10T15:52:01","slug":"valstybine-vaistu-kontroles-tarnyba-ispeja-del-kancerogenisku-vaistiniu-preparatu","status":"publish","type":"post","link":"https:\/\/www.pasveik.lt\/lt\/rekomenduojamos-naujienos\/valstybine-vaistu-kontroles-tarnyba-ispeja-del-kancerogenisku-vaistiniu-preparatu\/532\/","title":{"rendered":"Valstybin\u0117 vaist\u0173 kontrol\u0117s tarnyba \u012fsp\u0117ja d\u0117l kancerogeni\u0161k\u0173 vaistini\u0173 preparat\u0173"},"content":{"rendered":"<p><span><\/span><\/p>\n<p><span>Valstybin\u0117 vaist\u0173 kontrol\u0117s tarnyba\u00a0liepos 4 dien\u0105 paskelb\u0117 prane\u0161im\u0105 apie pavojingus sveikatai vaistinius preparatus, kuri\u0173 sud\u0117tyje yra valsartan :<\/span><\/p>\n<p><span>&#8222;Valstybin\u0117s vaist\u0173 kontrol\u0117s tarnybos prie Lietuvos Respublikos sveikatos apsaugos ministerijos\u00a0 (toliau \u2013 Tarnyba) vir\u0161ininko \u012fsakymu\u00a0<\/span><a href=\"http:\/\/vvkt.lt\/get_file.php?file=eUdHWXlweWxiYVdVbldwbnlkbWFhV1daWkpkc2FwMlRtWmhyMWNmUGFzT1htOGZRbktsdVoybXVicTZleld5dGxKSml6WldybXBObHBIRGJ4Y1J1enBhYm5jV2FsVzJnYUt5Y3BaYk9tbWhyMnBIWGFhSnUySnRqYmRPUmtXYlBtWkdkeUp5Zmw2UmduVyUyQnJuSkZzc0puS2xNcVVvMjNKWmFkdWxjUEliTXZIbnB2SHlHZHJibWhvYkd1YmxXeG5ZOVJweFdXZGNKOXRkV3JhbXRWbXc4U25sYzJlbjVpbFpLZVlXTXpMYWF4bHhaWE1hYkNlMFp1Vm50bVZncHpTeFpPYjFaeWhscDFrcEpxYWxzdG5wcFRaa3NxVlpYRFVaNWhzekptZGJaMlo=\">Nr. (1.4)1A-775<span>\u00a0<\/span><\/a><span>vaistini\u0173 preparat\u0173 registruotojai, j\u0173 atstovai Lietuvoje, lygiagretaus importo leidimo tur\u0117tojai, didmeninio platinimo ir vaistin\u0117s veiklos licencijos tur\u0117tojai \u012fpareigoti nutraukti tiekim\u0105 rinkai ir nedelsiant at\u0161aukti vaistinius preparatus, kuri\u0173 veiklioji med\u017eiaga<span>\u00a0<\/span><\/span><em>valsartanas<\/em><span><span>\u00a0<\/span>yra pagaminta gamybos vietoje Zhejiang Huahai Pharmaceutical Co. Ltd (BS 1) Chuannan Site, RC -317016\u00a0 CHUANNAN, DUQIAO, LINHAI, ZHEJIANG PROVINCE, Kinija, ir kurio CEP R1-CEP 2010-072-Rev 00 tur\u0117tojas yra Zhejiang Huahai Pharmaceutical Co. Ltd\u00a0 Xunquiao, RC -317024\u00a0 LINHAI CITY, ZHEJIANG PROVINCE, Kinija, nes veikliojoje med\u017eiagoje nustatyta priemai\u0161a N-Nitrosodimetylaminas\u00a0 yra kancerogeni\u0161ka \u017emon\u0117ms.&#8221;<\/span><\/p>\n<p><span>\u012edomu yra tai, kad \u0161i kancerogeni\u0161ka priemai\u0161a nerasta originaliuose valsartan\u00a0 turin\u010diuose vaistiniuose preparatuose.<\/span><\/p>\n<p>Valstybin\u0117 vaist\u0173 kontrol\u0117s tarnyba\u00a0 dar kart\u0105 \u012frod\u0117, kad ne visi vaistiniai preparatai su ta pa\u010dia veikl\u0105ja med\u017eiaga veikia\u00a0 vienodai. Deja, bet kai kurie i\u0161 j\u0173 yra netgi kancerogeni\u0161ki.<\/p>\n<p>Labai svarbu \u012fsp\u0117ti pacientus, kurie gydosi \u0161iais preparatais , gr\u0105\u017einti\u00a0\u012f vaistines\u00a0 pavojingus gyvybei valsartano turin\u010dius vaistinius preparatus.<\/p>\n<\/p>\n<p><span>\u0160iuo metu visos Europos nacionalin\u0117s vald\u017eios institucijos, \u012fskaitant Lietuv\u0105, at\u0161aukia vaistus, kuri\u0173 sud\u0117tyje yra valsartano, pagaminto Zhejiang Huahai Pharmaceuticals, Kinijoje.<br \/>\u00a0\u00a0<br \/><\/span><span>Per\u017ei\u016bra prasid\u0117jo po to, kai gamintojas nustat\u0117\u00a0 priemai\u0161\u0105 veikliojoje med\u017eiagoje valsartane, kuri\u0105 bendrov\u0117 tiekia gamintojams Europos S\u0105jungoje, gaminantiems kai kuriuos vaistus, kuri\u0173 sud\u0117tyje yra valsartano. Priemai\u0161\u0173 atsiradimas veikliojoje med\u017eiagoje buvo netik\u0117tas ir manoma, kad jis susij\u0119s su veikliosios med\u017eiagos gamybos b\u016bdo poky\u010diais.<br \/>\u00a0<br \/><\/span><span>Vaistai, kuri\u0173 sud\u0117tyje yra valsartano, yra skirti pacientams, turintiems auk\u0161t\u0105 kraujosp\u016bd\u012f, siekiant suma\u017einti komplikacijas, tokias kaip miokardo infarktas ir insultas. Jis taip pat skirtas pacientams, sergantiems \u0161irdies nepakankamumu ar neseniai patirtu miokardo infarktu.<br \/>\u00a0<br \/><\/span><span>Europos vaist\u0173 agent\u016bra toliau vertins, ar priemai\u0161os gali kelti bet kok\u012f pavoj\u0173 pacientams.<\/p>\n<p><\/span><b>Svarbu:<br \/><\/b><span>Netik\u0117ta priemai\u0161a buvo rasta veikliojoje med\u017eiagoje, naudojamoje<span>\u00a0<\/span><\/span><span>tik kai kuri\u0173 vaist\u0173<\/span><span>, kuri\u0173 sud\u0117tyje yra valsartano, gamybai.<br \/>\u00a0<br \/><\/span><span>Jums gali b\u016bti i\u0161duodamas kitas valsartano turintis vaistas arba skirtas alternatyvus gydymas, kai j\u016bs kreipsit\u0117s \u012f gydytoj\u0105 d\u0117l vaisto recepto i\u0161ra\u0161ymo.<br \/>\u00a0<br \/><\/span><span>Vaistai, kuri\u0173 sud\u0117tyje yra priemai\u0161\u0173 jau i\u0161imti i\u0161 rinkos, tad vaistin\u0117se esantys vaistai yra kokybi\u0161ki ir tinkami vartoti.<br \/>\u00a0<br \/><\/span><span>I\u0161 Lietuvos rinkos at\u0161aukiam\u0173 vaist\u0173 su valsartanu<span>\u00a0<\/span><a href=\"http:\/\/www.vvkt.lt\/get_file.php?file=eDJIR3lwJTJCbG1xVmduVzVuek5scWFXbVpZSmRyYXBxVG1aaHUxY2ZQWnNPWG01M1F5YWxyWjVhdWFxNmV6WmF0bUpKbXpaYXJucE5vcEc3Ync4UnV6c21ieDhYSGxXdWdaYXhzcGNyT2xtaGoybWZYYTZKcjJKcGptZFBIa1p6UHlaR1l5TWlmYmFSbG5XNnJ5SkZxc0d2S1pNcHJvMjNKYUtlYWxaZkltc3ZKbnBmSG0yZHBibUJvWm0yYmwyZG5iTnlXeldXcW05eWFiM0NubGRadTFjZVRsZGVjb1dlaGtabHVwWjdMWjJkbjNKYk5hS3B0M0d0dmI2R1Q=\">s\u0105ra\u0161<\/a><\/span><span><a href=\"http:\/\/www.vvkt.lt\/get_file.php?file=eDJIR3lwJTJCbG1xVmduVzVuek5scWFXbVpZSmRyYXBxVG1aaHUxY2ZQWnNPWG01M1F5YWxyWjVhdWFxNmV6WmF0bUpKbXpaYXJucE5vcEc3Ync4UnV6c21ieDhYSGxXdWdaYXhzcGNyT2xtaGoybWZYYTZKcjJKcGptZFBIa1p6UHlaR1l5TWlmYmFSbG5XNnJ5SkZxc0d2S1pNcHJvMjNKYUtlYWxaZkltc3ZKbnBmSG0yZHBibUJvWm0yYmwyZG5iTnlXeldXcW05eWFiM0NubGRadTFjZVRsZGVjb1dlaGtabHVwWjdMWjJkbjNKYk5hS3B0M0d0dmI2R1Q=\">as<\/a>.<br \/>\u00a0<\/span><\/p>\n<\/p>\n<p>Pasveik.lt info<\/p>\n","protected":false},"excerpt":{"rendered":"<p><span>Papildyta &#8222;Valstybin\u0117s vaist\u0173 kontrol\u0117s tarnybos prie Lietuvos Respublikos sveikatos apsaugos ministerijos\u00a0 (toliau \u2013 Tarnyba) vir\u0161ininko \u012fsakymu\u00a0<\/span><a href=\"http:\/\/vvkt.lt\/get_file.php?file=eUdHWXlweWxiYVdVbldwbnlkbWFhV1daWkpkc2FwMlRtWmhyMWNmUGFzT1htOGZRbktsdVoybXVicTZleld5dGxKSml6WldybXBObHBIRGJ4Y1J1enBhYm5jV2FsVzJnYUt5Y3BaYk9tbWhyMnBIWGFhSnUySnRqYmRPUmtXYlBtWkdkeUp5Zmw2UmduVyUyQnJuSkZzc0puS2xNcVVvMjNKWmFkdWxjUEliTXZIbnB2SHlHZHJibWhvYkd1YmxXeG5ZOVJweFdXZGNKOXRkV3JhbXRWbXc4U25sYzJlbjVpbFpLZVlXTXpMYWF4bHhaWE1hYkNlMFp1Vm50bVZncHpTeFpPYjFaeWhscDFrcEpxYWxzdG5wcFRaa3NxVlpYRFVaNWhzekptZGJaMlo=\">Nr. (1.4)1A-775<span>\u00a0<\/span><\/a><span>vaistini\u0173 preparat\u0173 registruotojai, j\u0173 atstovai Lietuvoje, lygiagretaus importo leidimo tur\u0117tojai, didmeninio platinimo ir vaistin\u0117s veiklos licencijos tur\u0117tojai \u012fpareigoti nutraukti tiekim\u0105 rinkai ir nedelsiant at\u0161aukti vaistinius preparatus, kuri\u0173 veiklioji med\u017eiaga<span>\u00a0<\/span><\/span><em>valsartanas<\/em><span><span>\u00a0<\/span>yra pagaminta gamybos vietoje Zhejiang Huahai Pharmaceutical Co. Ltd (BS 1) Chuannan Site, RC -317016\u00a0 CHUANNAN, DUQIAO, LINHAI, ZHEJIANG PROVINCE, Kinija, ir kurio CEP R1-CEP 2010-072-Rev 00 tur\u0117tojas yra Zhejiang Huahai Pharmaceutical Co. Ltd\u00a0 Xunquiao, RC -317024\u00a0 LINHAI CITY, ZHEJIANG PROVINCE, Kinija, nes veikliojoje med\u017eiagoje nustatyta priemai\u0161a N-Nitrosodimetylaminas\u00a0 yra kancerogeni\u0161ka \u017emon\u0117ms.&#8221;<\/span><\/p>\n","protected":false},"author":1,"featured_media":533,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27313],"tags":[26062,26061,26065,26063,26064,17080,138,26060],"site":[27309,27238],"post_item_type":[28490],"class_list":["post-532","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gydymo-naujienos","tag-chuannan","tag-huahai","tag-kancerogeniska","tag-linhai","tag-province","tag-turetojai","tag-vaistai","tag-zhejiang","site-imunitetas-lt","site-sindromas-lt"],"acf":{"post_sites":[27238,27309]},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/comments?post=532"}],"version-history":[{"count":0,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/532\/revisions"}],"acf:term":[{"embeddable":true,"taxonomy":"site","href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site\/27309"},{"embeddable":true,"taxonomy":"site","href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site\/27238"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media\/533"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/categories?post=532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=532"},{"taxonomy":"site","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site?post=532"},{"taxonomy":"post_item_type","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/post_item_type?post=532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}